B
BioSpace
J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
0:00-19:48
Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio buy and mixed data in a late-stage pulmonary fibrosis trial; Revolution Medicines’ newly approved pancreatic cancer drug works better for patients with certain mutations; and Caribou Biosciences may be on its way out.
Publisher
BioSpace
Published
October 14, 2026
Duration
20 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
B
BioSpace
@biospace
#jsdisappointingq3 #revmedssubgroupdata #bmsmixedresults #lifesciences
